Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
800-rhNGF+800-rhBDNF
- Development stage
- Preclinical
- Lead developer
- Manzanita Pharmaceuticals
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
800-rhNGF+800-rhBDNF is a dual-targeted fluorescence imaging agent developed by Manzanita Pharmaceuticals for intraoperative nerve visualization. The product consists of recombinant human nerve growth factor (rhNGF) and recombinant human brain-derived neurotrophic factor (rhBDNF), both conjugated to a near-infrared fluorescent dye (800 nm). By targeting the high-affinity neurotrophin receptors TrkA (NTRK1) and TrkB (NTRK2) expressed on nerve fibers, the agent allows for real-time identification of neuronal structures during surgery. This 'nerve paint' technology is intended to help surgeons avoid accidental nerve damage, thereby preventing post-operative complications such as paresthesias and other sensory or motor deficits. It is currently in the proof-of-concept (POC) stage of development for various surgical indications.
- Other names
- recombinant human nerve growth factor + recombinant human brain-derived neurotrophic factorNGF-BDNF-dye-conjugated neurotrophin combination800-rhNGF + 800-rhBDNF
02
Targets
NTRK1 (Tropomyosin-related receptor kinase A)NTRK2 (Tropomyosin-related kinase receptor type B)
Beyond the preview
Go deeper on 800-rhNGF+800-rhBDNF.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 800-rhNGF+800-rhBDNF.